News Center
With the tenet of "Healthy China, Dedicated commitment", Linuo Pharmaceuticals increases cooperation and association with external scientific research institutes while innovating and developing independently.
13
2024
-
11
Xi Bao | lino pharmaceutical fluoxetine hydrochloride dispersible tablets won another honor!
Classification：
News
行业新闻
Corporate News
Recently, the Jinan Science and Technology Association announced2024Annual Jinan CityAs a result of the mass technological innovation competition of "speaking of ideals and comparing contributions", the research and development of fluoxetine hydrochloride dispersible tablets won the second prize of excellent scientific and technological innovation project.
Jinan CityThe activity of "stressing ideals and comparing contributions" is a landmark mass technological innovation competition aimed at stimulating the enthusiasm of enterprises, institutions and individuals for scientific and technological innovation and promoting high-quality economic development. The event is committed to setting up advanced benchmarks in the industry and commending outstanding contributions. Its core focuses on cultivating outstanding innovative talents, promoting high-spirited innovation spirit, activating unlimited innovation potential, and carefully building a display of talents and practical innovation for scientific and technological workers. The broad platform, and then strongly promote the enterprise to become the leader and core driving force of technological innovation.
As an enterprise focusing on pharmaceutical R & D and production, lino pharmaceutical is committed to improving product quality and service through scientific and technological innovation, and providing better health solutions for patients. The award of fluoxetine hydrochloride dispersible tablets this time reflects the outstanding strength of linuo pharmaceutical in scientific and technological innovation, and also demonstrates its determination and sense of responsibility to provide high quality pharmaceutical products for the society and patients.
In the future development, lino pharmaceutical will continue to increase R & D investment and technological innovation, promote more products with independent intellectual property rights and core competitiveness to the market, and make greater contributions to the sustainable development of the industry and the health of the people.
Related news
2026-05-18
On May 16–17, Wu Xiaobo, known as “China’s foremost financial writer” and a renowned entrepreneur, led a delegation to visit and inspect Keyuan Pharmaceutical (stock code: 301281.SZ). The group focused on the company’s achievements in integrating smart manufacturing with digital AI technologies in the pharmaceutical sector, engaged in in-depth discussions with its core management team, and expressed high praise for the company’s practical approach to driving industrial upgrading through digital and intelligent transformation. Gao Yuankun, Chairman and President of Linuo Group, along with Li Hongfu, Chairman of Keyuan Pharmaceutical, and Wei Zhiguo, President of the company, accompanied the delegation during the visit.
ADD：#30766 Jingshidong Road, Linuo High-tech Park, Jinan, Shandong Province, P. R. China